Arthur has made over 22 trades of the Myriad Genetics stock since 2004, according to the Form 4 filled with the SEC. Most recently Arthur exercised 60,000 units of MYGN stock worth $706,800 on 9 February 2010.
The largest trade Arthur's ever made was exercising 120,000 units of Myriad Genetics stock on 27 March 2006 worth over $156,000. On average, Arthur trades about 20,508 units every 33 days since 2003. As of 9 February 2010 Arthur still owns at least 60,000 units of Myriad Genetics stock.
You can see the complete history of Arthur Hayes stock trades at the bottom of the page.
Arthur's mailing address filed with the SEC is C/O CELGENE CORPORATION, , WARREN, NJ, 11050.
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum, and Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
Myriad Genetics executives and other stock owners filed with the SEC include: